查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1293756

药物警戒市场：按类型（外包、内部）、临床试验（第一阶段、第二阶段、第三阶段）、按方法、最终用户 - 俄罗斯-乌克兰衝突和高通货膨胀 - 2023-2030 年世界预测

Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Method, End User - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球药物警戒市场规模将达到87,619.4亿美元，复合年增长率为15.40%，大幅增长，2030年将达到24,026.11百万美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球药物警戒市场至关重要。 通过检查业务战略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的具体需求做出明智的决策。 这种高级分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场份额分析

市场份额分析可以深入了解供应商在特定市场区域的当前状态。 比较供应商对整体收入、客户群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。 该分析还揭示了特定行业的竞争程度、积累和分散的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要公司所服务的市场的全面信息。

2. 市场开发：提供有关利润丰厚的新兴市场的详细信息，并分析其在成熟市场领域的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新开发和投资的详细信息。

4.市场趋势：全面了解俄罗斯-乌克兰衝突和高通胀。

5.竞争评估和信息：对主要公司的市场份额、战略、产品、认证、监管状况、专利状况、製造能力进行综合评估。

6. 产品开发和创新：提供对未来技术、研发活动和突破性产品开发的见解。

此报告回答了以下问题：

1.全球药物警戒市场规模及预测是多少？

2. 在预测期内，COVID-19 对全球药物警戒市场的抑制因素和影响是什么？

3. 在预测期内，全球药物警戒市场需要投资哪些产品/细分市场/应用/领域？

4. 全球药物警戒市场的竞争策略是什么？

5.全球药物警戒市场的技术趋势和监管框架是什么？

6.全球药物警戒市场主要厂商的市场份额是多少？

7.什么形式和战略举措被认为适合进入全球药物警戒市场？

目录

第一章前言

第二章研究方法

第 3 章执行摘要

第四章市场概述

第 5 章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病患病率不断上升
      • 自发报告和电子健康记录 (EHR) 挖掘中药物警戒应用的增加
      • 玩家对外包服务的需求不断增加
      • 不良反应和药物毒性的发生率增加
    • 抑制因素
      • 面向中小企业的高成本技术
    • 机会
      • 新冠肺炎 (COVID-19) 的出现带来了新机遇
      • 医疗保健公司增加研发 (R&D) 投资
    • 作业
      • 缺乏熟练劳动力
  • 市场趋势
  • 新冠肺炎 (COVID-19) 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通胀的累积影响
  • 波特五力分析
  • 价值炼和关键路径分析
  • 监管框架
  • 客户定制

第 6 章药物警戒市场：按类型

  • 合同工作外包
  • 内部

第七章临床试验药物警戒市场

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段
  • 临床前

第 8 章药物警戒市场：按方法

  • 监控群组事件
  • EHR 挖掘
  • 加强 ADR 报告
  • 自愿报告
  • 有针对性的自愿报告

第 9 章药物警戒市场：按最终用户划分

  • 学术研究所
  • 政府机构
  • 健康保险公司
  • 医院和护理机构
  • 製药和生物技术公司

第 10 章美洲药物警戒市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第11章亚太地区药物警戒市场

  • 澳大利亚
  • 中国
  • 印度
  • 印度尼西亚
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的药物警戒市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 意大利
  • 荷兰
  • 尼日利亚
  • 挪威
  • 波兰
  • 卡塔尔
  • 俄罗斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯联合酋长国
  • 英国

第13章竞争态势

  • FPNV定位矩阵
  • 市场份额分析：按主要公司划分
  • 竞争情景分析：主要公司

第14章上市公司名单

第15章附录

  • 讨论指南
  • 关于许可证和价格
Product Code: MRR-43676CF420AF

The Global Pharmacovigilance Market is forecasted to grow significantly, with a projected USD 8,761.94 million in 2023 at a CAGR of 15.40% and expected to reach a staggering USD 24,026.11 million by 2030.

The the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Pharmacovigilance Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Pharmacovigilance Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Contract Outsourcing and In-house. The Contract Outsourcing commanded largest market share of 75.46% in 2022, followed by In-house.

Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical. The Phase IV commanded largest market share of 38.59% in 2022, followed by Phase III.

Based on Method, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting. The Spontaneous Reporting commanded largest market share of 27.55% in 2022, followed by Intensified ADR Reporting.

Based on End User, market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies. The Pharma & Biotech Companies commanded largest market share of 49.80% in 2022, followed by Government Agencies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 37.17% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Pharmacovigilance Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pharmacovigilance Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmacovigilance Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmacovigilance Market?

4. What is the competitive strategic window for opportunities in the Global Pharmacovigilance Market?

5. What are the technology trends and regulatory frameworks in the Global Pharmacovigilance Market?

6. What is the market share of the leading vendors in the Global Pharmacovigilance Market?

7. What modes and strategic moves are considered suitable for entering the Global Pharmacovigilance Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Pharmacovigilance Market, by Type, 2022 vs 2030
  • 4.3. Pharmacovigilance Market, by Clinical Trial, 2022 vs 2030
  • 4.4. Pharmacovigilance Market, by Method, 2022 vs 2030
  • 4.5. Pharmacovigilance Market, by End User, 2022 vs 2030
  • 4.6. Pharmacovigilance Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the Prevalence of Chronic Diseases
      • 5.1.1.2. Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
      • 5.1.1.3. Rise in Demand for Outsourcing Services by Players
      • 5.1.1.4. Rising Incidence of ADR and Drug Toxicity
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost Technology for Small and Mid-sized Players
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of COVID-19 have Opened New Opportunities
      • 5.1.3.2. Rising Investment in Research and Development (R&D) by Healthcare Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Labor
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Pharmacovigilance Market, by Type

  • 6.1. Introduction
  • 6.2. Contract Outsourcing
  • 6.3. In-house

7. Pharmacovigilance Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-clinical

8. Pharmacovigilance Market, by Method

  • 8.1. Introduction
  • 8.2. Cohort Event Monitoring
  • 8.3. EHR Mining
  • 8.4. Intensified ADR Reporting
  • 8.5. Spontaneous Reporting
  • 8.6. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Government Agencies
  • 9.4. Health Insurance Companies
  • 9.5. Hospitals & Care Providers
  • 9.6. Pharma & Biotech Companies

10. Americas Pharmacovigilance Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

1. Accenture, PLC

2. Bristol Myers Squibb

3. C.H. Boehringer Sohn AG & Ko. KG

4. Capgemini SE

5. ClinChoice Inc.

6. F. Hoffmann-La Roche AG

7. GlaxoSmithKline PLC

8. HCL Technologies Limited

9. ICON PLC

10. Infosys Limited

11. International Business Machines Corporation

12. IQVIA

13. ITclinical

14. Laboratory Corporation

15. Linical Co., Ltd.

16. Novartis International AG

17. Oracle Corporation

18. Parexel International

19. Pfizer Inc.

20. Quanticate International limited

21. Sanofi S.A.

22. Syneos Health, Inc.

23. Take Solutions Ltd.

24. Tata Consultancy Services

25. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2030 (%)
  • FIGURE 6. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2030 (%)
  • FIGURE 7. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 8. PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. PHARMACOVIGILANCE MARKET DYNAMICS
  • FIGURE 10. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 8. PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 194. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 195. PHARMACOVIGILANCE MARKET LICENSE & PRICING